Also known as: CORDStrom
CORDStrom is an investigational off-the-shelf allogeneic pooled umbilical cord-derived mesenchymal stromal cell therapy platform from INmune Bio. It is being developed with initial focus on recessive dystrophic epidermolysis bullosa and is being prepared for UK/EU and U.S. regulatory submissions. The product is not yet approved.
INmune Bio will present new Phase III clinical data for its CORDStrom cell therapy for recessive dystrophic epidermolysis bullosa. The webinar on February 26, 2026, will feature investigators discussing outcomes including skin score improvements and quality-of-life measures. CORDStrom represents a systemic, disease-modifying alternative to topical treatments for this rare skin disorder.
INmune Bio announced FDA alignment on Phase III registration program for XPro1595 in Alzheimer's disease and submitted regulatory packages for CORDStrom in rare disease treatment, marking key milestones toward commercialization.
